To, Date: 2<sup>nd</sup> November, 2018

Department of Corporate Service (DCS-CRD),

**BSE Limited** 

Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001

Subject: Outcome of the Board Meeting Dated 2<sup>nd</sup> November, 2018.

Dear Sir,

This is to inform you that the Third Meeting of the Board of Directors of NGL Fine-Chem Limited for the financial year 2018-2019 held at the registered office of the Company on Friday, the November 2, 2018 at 4.00 p.m and concluded at 6.00 p.m approved the following:

- 1. Approved Standalone Unaudited Financial Results for the quarter and half year ended 30th September, 2018 pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirement) Regulations.
- 2. Approved the Statement of Assets and Liabilities for the half year ended 30<sup>th</sup> September, 2018.

Kindly take the same on your record and acknowledge receipt of the same.

**Thanking You,**Yours truly, **FOR NGL Fine-Chem Ltd** 

Esha Kulkarni Company Secretary/ Compliance Officer Regd. Office: 301, E - Square, Subhash Road, Vile Parle East, Mumbai 400057, Maharashtra, INDIA
Tel.: (+91 22) 26636450 Fax: 26108030 Email: info@nglfinechem.com CIN: L24110MH1981PLC025884, Website: www.nglfinechem.com

To,

Date: 2nd November, 2018

Department of Corporate Service (DCS-CRD),

**BSE Limited** 

Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001

Subject: Outcome of the Board Meeting Dated 2nd November, 2018.

Dear Sir,

This is to inform you that the Third Meeting of the Board of Directors of NGL Fine-Chem Limited for the financial year 2018-2019 held at the registered office of the Company on Friday, the November 2, 2018 at 4.00 p.m and concluded at 6.00 p.m approved the following:

- Approved Standalone Unaudited Financial Results for the quarter and half year ended 30th September, 2018 pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirement) Regulations.
- 2. Approved the Statement of Assets and Liabilities for the half year ended  $30^{th}$  September, 2018.

Kindly take the same on your record and acknowledge receipt of the same.

Thanking You,

Yours truly,

FOR NGL Fine-Chem Ltd

Esha Kulkarni

Company Secretary/ Compliance Officer



# MANEK & ASSOCIATES

**CHARTERED ACCOUNTANTS** 

Off. # 2618 5110 # 2618 5137 Fax # 2618 4912 shailesh.manek@gmail.com www.camanek.com

3, Shanti Kunj, 17, Prarthana Samaj Road, Vile Parle (East), Mumbai - 400 057.

SHAILESH MANEK

B.Com.(Hons), Grad. C.W.A., F.C.A.

## LIMITED REVIEW REPORT OF THE AUDITORS

Review Report to, The Board of Directors, NGL Fine-Chem Limtied

We have reviewed the accompanying statement of Unaudited Financial Results ('the Statement') of NGL Fine-Chem Limited ("the Company") for the quarter ended SEPTEMBER 30, 2018., prepared and being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI ((Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by SEBI circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016, which has been initiated by us for the purpose of identification.

This statement is the responsibility of the Company's Management and has been reviewed by the Audit Committee, at its meeting held on November 2nd, 2018 and, approved by the Board of Directors, at its meeting held on November 2<sup>nd</sup>, 2018. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE)2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Accounting Standards, i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014- and other recognised accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by SEBI circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

> COUNTANTS FIRM No.

For MANEK & ASSOCIATES **Chartered Accountants** Firm's Registration No.:126679W ma

MUMBAI DATED: 02/11/2018 (SHAILÆSH MANEK) **Proprietor** 

Membership Numbe:.034925

#### **NGL FINE-CHEM LIMITED**

Regd Office: 301 E Square, Subhash Road

Vile Parle ( East), Mumbai 400 057



#### STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30th SEPT 2018

0

20.38

8.53

Rupees in lakhs Half Year Ended Year Ended Quarter Ended 30.09.2017 31.03.2018 30.09.2018 30.06.2018 30.09.2017 30.09.2018 (Unaudited) (Unaudited) (Audited) (Unaudited) (Unaudited) (Unaudited) 2,890.57 7,378.04 5,014.87 11,567.81 1 Revenue from Operations 3.892.04 3,486,00 102.56 220.48 257.15 П Other Income 184.37 217.77 402.14 III Total Revenue (I+II) 4,076.41 3,703.77 2,993.13 7,780.18 5,235.35 11,824.96 IV Expences: 3,178.29 2,098.38 5,038.07 a) Cost of Material Consumed 1,555.73 1,622.56 1,096.49 b) (Increase)/Decrease in stock in trade and work in progress 128.44 (11.57)(20.80)(451.38 139.90 (151.47)c) Excise Duty paid 201.93 867.05 1,837.17 d) Employee benefits expenses 566.88 481.39 456.28 1,048.27 58.65 15.46 111.04 30.26 155.50 e) Finance Costs 52.39 306.46 246.93 456.07 f) Depreciation and amortisation expenses 149.43 157.03 166.26 1.954.08 1,262,92 2,807.32 g) Other expenses 940.30 1,013.78 616.78 2,479.71 6,586.57 4,484.74 10,044.68 Total Expenses (IV) 3,404.63 3,181.94 671.78 1,193.61 750.61 1,780.28 Profit/(loss) before exceptional items and tax (III-IV) 521.83 513.42 VI Exceptional Items VII Profit/(loss) Before Tax (V-VI) 671.78 521.83 513.42 1,193.61 750.61 1,780.28 VIII Tax Expense (381.00 (400.00)(149.00)a) Current Tax (220.00)(180.00)(88.00)b) MAT Tax 57.00 b) Prior Years 4.88 5.08 5.08 130.72 (77.52)(202.06 c) Deffered Tax (9.91)140.63 (85.85)441.87 482.46 344.65 924.33 528.97 1,259.30 Profit/ (Loss) for the period from continuing operations (VII-VIII) X Other Comprehensive Income (1.00)5.40 a. Gain/(Loss) on actuarial valuation of post employment benefits (4.50)23.11 (1.76)18.61 (0.61)(5.42)(0.87)(1.50 b. Deferred tax on above 1.31 (6.73)13.19 (1.87)3.90 c. Other Comprehensive Income (Net of Tax) (3.19)16.38 (2.37)937.52 527.10 1,263.20 XI Total Comprehensive Income 438.68 498.84 342.28 308.90 308.90 308.90 XII Paid-up Equity Share Capital (Face Value of the Share Rs. 5/- each) 308.90 308.90 308.90 Reserves excluding Revaluation Reserve as per balance sheet of XXIII N.A N.A N.A. 6,895.28 N.A N.A previous accounting year XIV Earnings Per Share (EPS) a) Basic 7.81 5.54 14.96 8.53 20.38 7.15

7.15

7.81

5.54

14.96

b) Diluted



### NGL FINE-CHEM LIMITED

Regd Office: 301 E Square, Subhash Road

Vile Parle ( East), Mumbai 400 057



STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30th SEPT 2018

Statement of Assets & Liabilities of NGL Fine-Chem Limite Standalone Statement of Assets & Liabilities	6760	- Laliba	
Standardie Statement of Assets & Liabilities		Rupees In Lakhs	
	As at half year	As at year	
	ended	ended	
PARTICULARS	30.09.2018	31.03.2018	
	UN-AUDITED	AUDITED	
ASSETS			
1 . Non-current assets	5 250 40	5,614.49	
(A) Property, Plant and Equipment	5,250.49	329.22	
(B) Capital work-in-progress	414.20	329.22	
(C) Investment Property			
(D) Goodwill			
(E) Other Intangible assets	45.00	17.99	
(F) Intangible assets under development	15.90	17.99	
(G) Biological Assets other than bearer plants			
(H) Financial Assets			
(i) Investments			
(ii) Trade receivables			
(iii) Loans	1		
(iv) Others	998.06	1,314.88	
(I) Deferred tax assets (net)			
(J) Other non-current assets	131.96	38.40	
2. Current assets	~		
(A) Inventories	1,896.79	1,681.05	
(B) Financial Assets		02.000.000	
(i) Investments	728.66	647.75	
(ii) Trade receivables	3,460.00	2,766.73	
(iii) Cash and cash equivalents	88.46	148.63	
(iv) Bank balances other than(iii) above	223.36	223.36	
(v) Loans	1		
(vi) Others (to be specified)	98.15	95.24	
(C) Current Tax Assets (Net)			
(D) Other cufrent assets	513.89	51.34	
(-,			
Total Assets	13,819.92	12,929.08	
EQUITY AND LIABILITIES			
1. Equity	200.00	308.90	
(A) Equity Share capital	308.90		
(B) Other Equity	7,832.81	6,895.2	
	1		
2. Liablities			
(I) Non-current liabilities	1		
(A) Financial Liabilities			
(i) Borrowings	994.48	1,236.0	
(ii) Trade payables	1		
(iii)Other financial liabilities	1		
(B) Provisions	133.31	148.8	
(C) Deferred tax liabilities (Net)	157.93	283.2	
(D) Other non-current liabilities	18.92	12.3	
		1	
(II) Current liabilities			
(A) Financial Liabilities			
(i) Borrowings	1,618.37		
(ii) Trade payables	2,098.10		
(iii) Other financial liabilities	550.44		
(B) Other current liabilities	30.83		
(C) Provisions	28.26		
(d) Current Tax Liabilities (Net)	47.5	B 4.5	
	42 040 0	12 020	
Total Equity and Liabilities	13,819.9	3 12,930	

#### Notes:

- The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Friday, 2nd November, 2018. These results are subjuted Review by the Statutory Auditors of the Company.
- The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 "Operating Segment" notified pursu to Companies (Indian Accounting Standards) Rule 2015.
- At one of the units in Tarapur, an incidence of fire occurred leading to loss which is accounted under 'Other Ependiture' and is estimated net of insurance claim receivable. The loss for the quarter is estimated at Rs.130.44 lakhs and for the half year at Rs. 254.92 lakhs.
- 4 Previous period figures have been regrouped/rearranged wherever necessary.

Place: Mumbai Date: 02-Nov-18 For and On behalf of Board of Direct

Rahul Nach Managing Dire